Which impact for proton pump inhibitors in SARS-COV-2 pneumonia
Open Access
- 19 October 2021
- journal article
- review article
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 91 (4)
- https://doi.org/10.4081/monaldi.2021.1803
Abstract
Identification of risk factors for severe outcome of Sars-Cov-2 infection is an important issue in COVID-19 management. Much attention has been focused on comorbidities as well as drugs taken by patients. Usage of proton pump inhibitors (PPIs) appears to potentially influence disease course. These drugs are known to reduce stomach acid and also modulate the immune system. Their use, prior to and during COVID-19 infection, seems to predispose to the development of more severe pneumonia and therefore to a greater risk of mortality. Instead, the use of Histamine receptor 2 antagonists (H2RAs) seems to be associated with a better outcome in patients with COVID-19, in terms of symptoms, risk of intubation and death. As PPIs are essential for treatment of many disorders, usage of these drugs should be balanced considering the benefits and risk ratio, in order to guarantee their correct use for the necessary time. It remains to be clarified whether the detrimental effects, in terms of COVID19 severe outcome, are due to PPIs or to the underlying disease for which they are administered. New controlled-randomized trials are required to better understand their impact in SARS-COV-2 infections. *Vanvitelli/Monaldi COVID Group: Adriano Cristinziano, Carolina Delle Donne, Cecilia Calabrese, Fabio Perrotta, Filippo Scialò, Francesco Lassandro, Gennaro Mazzarella, Giorgio Paoli, Leonardo De Luca, Maria Galdo, Miriam Buonincontro, Roberta Cianci, Rosalba Donizzetti, Stefano Sanduzzi Zamparelli, Tullio Valente, Vito D’Agnano, Vittorio BisogniKeywords
This publication has 71 references indexed in Scilit:
- Mast cells and inflammationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysisCMAJ : Canadian Medical Association Journal, 2010
- Gastric acid reduction leads to an alteration in lower intestinal microfloraBiochemical and Biophysical Research Communications, 2009
- Proton pump inhibitors in GORD: An overview of their pharmacology, efficacy and safetyPharmacological Research, 2009
- Proton Pump (H+/K+-ATPase) Expression in Human Laryngeal Seromucinous GlandsOtolaryngology -- Head and Neck Surgery, 2005
- Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive DrugsJAMA, 2004
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- Angiotensin II generation by mast cell α- and β-chymasesBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- The effect of omeprazole on human natural killer cell activityGeneral Pharmacology: The Vascular System, 1995